GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Net Margin %

Kyverna Therapeutics (Kyverna Therapeutics) Net Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Kyverna Therapeutics's Net Income for the three months ended in Mar. 2024 was $-26.69 Mil. Kyverna Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Kyverna Therapeutics's net margin for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Kyverna Therapeutics's Net Margin % or its related term are showing as below:


KYTX's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -152.785
* Ranked among companies with meaningful Net Margin % only.

Kyverna Therapeutics Net Margin % Historical Data

The historical data trend for Kyverna Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Net Margin % Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Net Margin %
-465.88 -411.29 -

Kyverna Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Net Margin % Get a 7-Day Free Trial -3,012.77 - - - -

Competitive Comparison of Kyverna Therapeutics's Net Margin %

For the Biotechnology subindustry, Kyverna Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyverna Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyverna Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Kyverna Therapeutics's Net Margin % falls into.



Kyverna Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Kyverna Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-60.366/0
= %

Kyverna Therapeutics's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin=Net Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-26.693/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kyverna Therapeutics  (NAS:KYTX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Kyverna Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, STE 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines